156 related articles for article (PubMed ID: 33017690)
1. Analysis of clinical trials of new drugs in China as of 2019.
Lin L; Chen Y; Yan L; Liu Y; Ni J; Yang H; Li H
Drug Discov Today; 2020 Dec; 25(12):2080-2088. PubMed ID: 33017690
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Clinical Trials of New Drugs for Liver Diseases in China.
Lin L; Li H
Drug Des Devel Ther; 2021; 15():3181-3191. PubMed ID: 34321867
[TBL] [Abstract][Full Text] [Related]
3. Evolution of ischemic stroke drug clinical trials in mainland China from 2005 to 2021.
Bo C; Wang T; Hou C; Han J; Chen L; Zhang H; Wang L; Li H
CNS Neurosci Ther; 2022 Aug; 28(8):1229-1239. PubMed ID: 35642775
[TBL] [Abstract][Full Text] [Related]
4. Trends in innovative pediatric drug development in China based on clinical trial registration data.
Wu WW; Ji X; Mou XS; Ma XY; Huang YT; Zhang JY; Zhang JX; Xie XR; Mao NY; Xu J
Front Med (Lausanne); 2023; 10():1187547. PubMed ID: 37484857
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials of orphan drugs in China over the decade 2012-2022: Opportunities and challenges.
Wu X; Xu W; Yu M; Zhang F; Wang H
Pharmacol Res; 2022 Aug; 182():106349. PubMed ID: 35835367
[TBL] [Abstract][Full Text] [Related]
6. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
7. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
Li N; Huang HY; Wu DW; Yang ZM; Wang J; Wang JS; Wang SH; Fang H; Yu Y; Bai Y; Yan Z; Cao Y; Jiang M; Liu YF; Li KY; Xu BH; Sun Y; He J
Lancet Oncol; 2019 Nov; 20(11):e619-e626. PubMed ID: 31674320
[TBL] [Abstract][Full Text] [Related]
8. Review of the Chinese Landscape in Phase 1 Clinical Trials for Noncancer Innovative Drugs Over 2015 to 2020.
Wu X; Zhang F; Yu M; Wang H
Clin Pharmacol Drug Dev; 2022 Aug; 11(8):903-909. PubMed ID: 35711154
[TBL] [Abstract][Full Text] [Related]
9. Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011-2020).
Chen C; Lou N; Zheng X; Wang S; Chen H; Han X
Front Med (Lausanne); 2021; 8():777698. PubMed ID: 34977078
[No Abstract] [Full Text] [Related]
10. [Development of clinical trial of new drugs of traditional Chinese medicines].
Yang ZQ; Tang YQ; DU YP; Tang HM; Zhang L; Gao R; Hu SY; Tang JY; Yuan WA
Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(7):1691-1695. PubMed ID: 33982470
[TBL] [Abstract][Full Text] [Related]
11. Current situation of clinical trials in Beijing and Shanghai, China.
Yoshida Y; Xue D; Yoshida Y; Zhang Y; Ma D; Sato Y; Wang P
Int J Clin Pharmacol Ther; 2013 May; 51(5):433-40. PubMed ID: 23547853
[TBL] [Abstract][Full Text] [Related]
12. [Progress on clinical trials of common gastrointestinal cancer drugs in China from 2012 to 2021].
Huang HY; Wu DW; Zhu Q; Yu Y; Wang HX; Wang J; Ga M; Meng XY; Du JT; Miao SM; Zhao ZX; Wang X; Shang P; Guo MJ; Liu LH; Tang Y; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):276-281. PubMed ID: 35316878
[No Abstract] [Full Text] [Related]
13. The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009-2021.
Li C; Hao J; Zheng Y; Wang C; Yang J; Wang W; Zhang K; Shao C; Hui W; Wang J; Li W; Tang YD
Diabetol Metab Syndr; 2023 Apr; 15(1):66. PubMed ID: 37005689
[TBL] [Abstract][Full Text] [Related]
14. Orphan Drugs and Their Impact on Pharmaceutical Development.
Attwood MM; Rask-Andersen M; Schiöth HB
Trends Pharmacol Sci; 2018 Jun; 39(6):525-535. PubMed ID: 29779531
[TBL] [Abstract][Full Text] [Related]
15. [Progress on clinical trials of cancer drugs in China, 2020].
Wu DW; Huang HY; Tang Y; Wang HX; Wang J; Wang SH; Fang H; Yang XY; Li J; Wang X; Liu LJ; Yan Y; Wang Q; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2021 Feb; 43(2):218-223. PubMed ID: 33601488
[No Abstract] [Full Text] [Related]
16. [How to adapt to the requirements of "clinical value-oriented drug innovation" for pharmaceutical research in application process of new traditional Chinese medicine].
Jin F
Zhongguo Zhong Yao Za Zhi; 2017 May; 42(9):1797-1802. PubMed ID: 29082710
[TBL] [Abstract][Full Text] [Related]
17. Changes in clinical trials of endocrine disorder and metabolism and nutrition disorder drugs in mainland China over 2010-2019.
Liu X; Wu S; Sun J; Ni S; Lu L; Hu W; Wei H; Zou Y; Li T; Li J; Mijiti B; Fang P; Zhao L; Zhou H; Xing X; Niu H; Cao Y
Pharmacol Res Perspect; 2021 Apr; 9(2):e00729. PubMed ID: 33660404
[TBL] [Abstract][Full Text] [Related]
18. [Communication in process of R&D and registration of new drugs of traditional Chinese medicine].
Han L; Hou CC
Zhongguo Zhong Yao Za Zhi; 2021 Feb; 46(3):730-735. PubMed ID: 33645041
[TBL] [Abstract][Full Text] [Related]
19. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
20. Progress on research and development in diabetes mellitus.
Zhang LW; Ruan MH; Liu JL; He CH; Yu JR
Yi Chuan; 2022 Oct; 44(10):824-839. PubMed ID: 36384721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
